Company Filing History:
1 out of 832,761 Years Active: 2003
Title: May Griffith - Innovator in Corneal Research
Introduction
May Griffith is a prominent inventor based in Ottawa, Canada. She has made significant contributions to the field of ophthalmology, particularly in the development of artificial corneas. Her innovative work aims to improve the quality of life for individuals suffering from corneal diseases.
Latest Patents
May Griffith holds a patent for an artificial cornea. This invention provides an in vitro avascular human corneal equivalent that comprises immortalized human cell lines. As these corneal equivalents are in vitro models, they are maintained in an incubator throughout the testing period, thereby eliminating the problems and expense associated with animal care. The corneal equivalent is preferably surrounded by a matrix in which angiogenesis can occur in vitro. This surrounding matrix has the potential to play the role of a pseudo-sclera, allowing the in vitro assessment of the cornea's angiogenic reaction to any substance or injury. Furthermore, the model is capable of being produced easily, is physiologically functional, and can give predictable and quantifiable results when submitted to various drugs, chemicals, and/or physical trauma. Modifications can be made, such as the use of primary donor cells instead of cell lines, and the physical and chemical treatments of the matrix material to make the constructs suitable for use in transplantation.
Career Highlights
Throughout her career, May Griffith has focused on advancing corneal research and developing innovative solutions for eye care. Her work has garnered attention in the scientific community, and she continues to be a leading figure in her field.
Collaborations
May Griffith has collaborated with notable colleagues, including Mitchell Watsky and Charles J Doillon. These partnerships have contributed to the advancement of her research and the development of her patented technologies.
Conclusion
May Griffith's contributions to the field of artificial corneas represent a significant advancement in ophthalmology. Her innovative approach to creating in vitro models has the potential to revolutionize the way corneal diseases are treated.